Biocartis, an innovative molecular diagnostics company, announced on November 28th (16:30CET) its intention to raise ca. € 60 million in a private placement through an accelerated book building, with the possibility to increase the size of the placement. The offering closed by 19:30CET on the same day.
Following strong demand and a significant oversubscription, it was decided to upsize the placement to € 80 million at a price of € 12.50 per share, implying a discount of 7.6% versus the prior day closing price or a mere 2.9% versus the prior month average price. The new shares were placed with ca. 75 Belgian, European and US institutional investors.
After having contributed to to the successful IPO and private placement of Biocartis in April 2015 and November 2016 respectively, Degroof Petercam also played a part in supporting Biocartis in this private placement.
Degroof Petercam is once more very pleased with the success of this transaction, which once again demonstrates its continuous commitment to life sciences companies.